Teva announced the launch of a generic version of EXJADE® (deferasirox) Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, in the U.S.
Deferasirox Tablets for Oral Suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older.
“We’re proud to offer an affordable generic treatment option with the launch of Deferasirox Tablets for Oral Suspension in the U.S.,” said Brendan O’Grady, EVP and Head of North America Commercial. “We continue striving to enable access to medicines for people living with chronic, complex conditions.”
With nearly 500 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
EXJADE® had annual sales of $134 million in the U.S., according to IQVIA data as of December 2018.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!